Otomastoiditis caused by *Sphingomonas paucimobilis*: case report and literature review

Gabriel Nuncio Benevides\(^a\), Noely Heina, Denise Swei Lo\(^b\), Angela Esposito Ferronato\(^b\), Selma Lopes Betta Ragazzi\(^b\), Cristina Ryoka Miyao Yoshiokab, Maki Hirose\(^b\), Debora Morais Cardoso\(^b\), Silvia Regina dos Santos\(^c\), Alfredo Elias Giliob,d

Benevides GN, Hein N, Lo DS, et al. Otomastoiditis caused by *Sphingomonas paucimobilis*: case report and literature review. Autopsy Case Rep [Internet]. 2014;4(3):13-20. http://dx.doi.org/10.4322/acr.2014.024

ABSTRACT

*Sphingomonas paucimobilis* is an aerobic Gram-negative bacillus that, although rare in humans, most commonly infects immunocompromised and hospitalized patients. Among the 59 pediatric cases of *S. paucimobilis* infection reported in the literature, the most common diagnosis involves isolated bacteremia. These cases are related to sporadic or epidemic infections. Death related to this infection occurred in only one case. The authors report a case of an 11-year-old boy with the diagnosis of *Sphingomonas paucimobilis* otomastoiditis and a thorough review of the literature on this infection in pediatrics. The patient presented a 20-day history of fever, otalgia, otorrhea, and progressive retroauricular swelling with protrusion of the left ear; despite 15 days of amoxicillin regimen. His past medical history included chronic bilateral otitis media, but no cause of immunosuppression was found. A brain computed tomography scan showed left otomastoiditis associated with a large circumscribed fluid collection with deep involvement of the soft tissues of the temporal region, including the subperiosteal space. Blood tests showed neutrophilia and elevated C-reactive protein. Surgical manipulation of the cited collection drained a large amount of a fetid purulent secretion. Ceftazidime and clindamycin were empirically initiated. The outcome was favorable, with fever defervescence and resolution of the scalp deformation. Culture of the drained secretion was positive for *S. paucimobilis*. Ciprofloxacin was scheduled for a further 10 days after discharge. The follow-up showed complete recovery. As far as we know, this is the first case of *S. paucimobilis* otomastoiditis, complicated with subperiosteal abscess in an immunocompetent child. The authors call attention to the increasing number of reports on *S. paucimobilis* infection over the years, and therefore to the importance of this pathogen, which was previously underestimated.

Keywords
Humans; Child; Sphingomonas; Gram-negative Bacterial Infections; Immunocompromised Host.

\(^a\) Department of Pediatrics – Hospital das Clínicas – Faculdade de Medicina – Universidade de São Paulo, São Paulo/SP – Brazil.
\(^b\) Department of Pediatrics – Hospital Universitário – Universidade de São Paulo, São Paulo/SP – Brazil.
\(^c\) Microbiology Laboratory – Hospital Universitário – Universidade de São Paulo, São Paulo/SP – Brazil.
\(^d\) Department of Pediatrics – Faculdade de Medicina – Universidade de São Paulo, São Paulo/SP – Brazil.
INTRODUCTION

Infection by *Sphingomonas paucimobilis* is rare. Although it occurs mostly in immunocompromised patients, cases of infected immunocompetent patients have been reported. We present a case of subperiosteal abscess due to a complicated otomastoiditis in an immunocompetent child. No previous case of subperiosteal abscess or otomastoiditis caused by *S. paucimobilis* has been reported. *S. paucimobilis* infection reports have been increasing in pediatric cases, encouraging us to conduct a literature review accompanied by the analysis of the clinical, demographic, and treatment data of the retrieved pediatric case report. We searched the PubMed and Google Scholar databases using the terms *"Sphingomonas paucimobilis", "Pseudomonas paucimobilis", "Sphingomonas," and "paucimobilis"*; checking out the references of each elected article for any paper that could have been missed. All available publications related to *S. paucimobilis* infection in children, from 0 to 18 years, were retrieved.

To the best of our knowledge, this is the first review of pediatric infections due to these bacteria.

CASE REPORT

An 11-year-old boy was brought to the emergency department with a 20-day history of fever, otalgia, otorrhea, and progressive retroauricular swelling, displacing the left ear anteriorly and downwards (Figure 1).

He was previously prescribed amoxicillin for 15 days without improvement. He lived in an orphanage and his HIV serology was negative. He had a previous diagnosis of bilateral chronic otitis media, but no other comorbidity was present. A computed tomography (CT) scan was performed (Figure 2) showing left otomastoiditis associated with a large fluid collection involving the subperiosteal layer of the temporal bone and the surrounding soft tissues, measuring 10.1 x 6.0 x 2.2 cm. Blood tests showed a white blood count of 22.4 x 10^3/mm^3 (reference value [RV]: 4.5-11.0 x 10^3/mm^3) (neutrophils 81.2%; RV: 40-70%) and C-reactive protein of 142 mg/L (RV: < 5 mg/L).

Surgical intervention on the retroauricular mass found a large amount of fetid and purulent secretion, a sample of which was sent off for microbiology studies. Ceftazidime and clindamycin were empirically started. The outcome was successful immediately after the surgical procedure, with fever defervescence, and normalization of blood tests. After 8 days of incubation, the culture of purulent secretion was positive for *S. paucimobilis*, but unfortunately, the antibiogram could not be tested because the bacteria in the culture media was no longer available. Therefore, based on literature data, we decided to maintain the initial antibiotic regimen and discharged the patient on the tenth day of hospitalization, scheduling 10 more days of oral ciprofloxacin to be taken at home.

METHODS

We searched PubMed, Google Scholar and LILACS databases using the terms *"Sphingomonas paucimobilis", "Pseudomonas paucimobilis", "Sphingomonas" and "paucimobilis"*. The references of each selected article were checked out in order to

Figure 1. 3D reformation of the mastoid computed tomography showing the bulging tumoral mass displacing the left ear downwards and anteriorly.
avoid missing any other paper. From a total of 1699 articles, 20 were related to *Sphingomonas paucimobilis* infection in children and adolescents up to 18 years, and therefore were selected.

**DISCUSSION**

The genus *Sphingomonas* comprises 13 Gram-negative, non-fermentative, non-sporing, oxidase- and catalase-positive bacilli. *Sphingomonas paucimobilis* is slightly motile (thus paucimobilis) and forms yellow pigmented colonies in blood agar.\(^1\) It was believed that *S. paucimobilis* was the only specimen of clinical importance; however, recently *Sphingomonas mucosissima* and *Sphingomonas adhesiva* also have been related to human infection.\(^2,3\) These bacilli are ubiquitous in nature (especially in water and soil) and in nosocomial environments causing mild-to-severe community and nosocomial illnesses.\(^1,4\)

First described by Holmes et al.\(^5\) in the 1970s as *Pseudomonas paucimobilis*, it was later reclassified as *Sphingomonas paucimobilis* in accordance with phylogenetic data by Yabuuchi et al.\(^6\) in the 1990s. Curiously, this bacteria was related to the death of the coral reef on the coast of Florida, USA.\(^7\)

The full-automated microbiology identification systems like “autoSCAN-W/A” and the “Vitek GN1,” may fail to identify some genera and species. Sung et al.\(^8\) showed that the major misidentified bacteria were the Gram-negative non-fermentative, especially *S. paucimobilis* in the autoSCAN-W/A system.

**Figure 2.** Computed tomography of the mastoid. **A** and **B** - Coronal plane. **C** and **D** - Axial plane. **D** represents the bone window. Arrow 1 shows the erosion of the temporal bone; arrow 2 the external ear canal. The abscess is connected with the mastoid do to the erosion of the temporal bone. The collection involved all soft tissues of the temporal region limited externally by the skin.
In 1979, the case of an infected leg ulcer of a Japanese seaman in Australia, was the first reported human infection.9 In 1981, the first pediatric colonization case by this bacteria was reported,10 but only in 1988 did Tiffany and Kline11 describe the first pediatric case of *S. paucimobilis* infection related to a brain abscess in a 6-year-old boy after a head trauma. Since then, the reports on this infection has increased, totaling 59 reported cases in pediatrics to date. Before 1980, no *S. paucimobilis* infection in children was reported. One case was reported between 1981 and 1990, three cases between 1991 and 2000, 28 cases between 2001 and 2010, and 27 cases between 2011 and March 2014, including ours (Figure 3). Despite the reported cases of infections, numerous cases of colonization by this bacteria were also published.10,12,13

Table 1 lists all elected cases of pediatric *S. paucimobilis* infection retrieved in our review. Table 2 summarizes the demographic and clinical data. The median age was 4.4 years (ranging from 3 days to 17 years); 22 cases occurred during the neonatal period (37.3%). The observed male:female ratio was 1.7:1.0. Hospital-acquired disease was identified in 66.1% and previous comorbidities were present in all of those patients.

The most common infection site was primary bacteremia (74.6%) followed by catheter-related bloodstream infection (10.2%), urinary tract infection (3.4%) and one case (1.7%) of each of the following: peritonitis related to continuous ambulatory peritoneal dialysis, cervical adenitis, central nervous system (CNS) infection, CNS abscess, osteomyelitis/septic arthritis, pneumonia, and otomastoiditis. Prematurity was the commonest associated comorbidity observed in 16 cases (41%); 13 cases were associated with malignancy (33%), out of which all were from the hematopoietic system; 2 cases (5.2%) occurred in children with Down syndrome, 2 cases (5.2%) with gut malformations, and 6 cases associated with other isolated diseases.

*S. paucimobilis* has been isolated from blood, sputum, urine, wound, ascitic liquid, cerebrospinal fluid, synovial liquid, and purulent secretion (brain, bone, and mastoid).11,14-23

Some studies associate *S. paucimobilis* outbreaks with contamination of the nosocomial environment; however, none of the reviewed papers demonstrated the same strain of the contamination with those of the infection site.17,18,20,24 Consequently, the endogenous source of the infection is the current theory on the route of infection.17,23 In addition, infection was also related to hospitalization, indwelling devices, and previous comorbidities, but our own case and other recent studies show that community-acquired infections are more prevalent than previously thought.19,25

Although Gram-negative infections frequently result in significant morbidity and mortality, *S. paucimobilis* infections seem to show a low rate of complications and a favorable prognosis.16,19,21,24,25 Only one case of pediatric death has been reported related to *S. paucimobilis* infection, which occurred in a premature neonate with septic shock.20 It is supposed that this low virulence is caused by the presence of atypical lipopolysaccharide in the outer membrane, a deficiency of bacterial endotoxins, and a different enzyme profile.6,26,27

*S. paucimobilis* antibiotic susceptibility varies according to the study. In general, they are significantly resistant to cephalosporin, especially the third generation, as well as to penicillins. Lin et al.19 showed that all isolated bacteria produced β-lactamase; however, other studies showed a resistance to cephalosporins of around 20%.21,22 There is also reported resistance to aminoglycosides, quinolones, trimethoprim, and sulfamethoxazole, and lesser to carbapenems.4,14-18,21,22 In previous studies, the recommendation of initial antibiotic therapy was a third generation cephalosporin added to an aminoglycoside; however, more current studies suggest that carbapenems or quinolones show a better susceptibility pattern.4,16,17,22

Despite supposed initial inappropriate antibiotic therapy reported in some cases of the literature, none presented any complication due to the delayed institution of the appropriate treatment.21,22 Since antibiotic resistance varies, treatment should be guided by the susceptibility test results of each case.4,16

**Figure 3.** The number of reported pediatric cases of *S. paucimobilis* infection from 1980 until March 2014.
Table 1. Cases of *S. paucimobilis* infection in children, since the first publication in 1988 until March 2014

| Condition                      | Age | Gender | Underlying conditions | Therapy                           | Country       | Source of outbreak | Number of patients | Reference |
|-------------------------------|-----|--------|-----------------------|-----------------------------------|---------------|-------------------|--------------------|-----------|
| CR-BSI                        | 14y | -      | Acute myeloid leukemia| Trimethoprim-Sulfamethoxazole     | Saudi Arabia  | Hospital          | 1                  | 14        |
| Osteomyelitis/septic arthritis| 16y | M      | ALL                   | Amikacin/Ceftazidime              | United Kingdom | **                | 1                  | 15        |
| Bacteremia                    | <1y | F      | Chylothorax           | Not described                     | Korea         | Hospital          | 1                  | 16        |
| Bacteremia                    | 2y  | F      | Aplastic anemia       | Not described                     | Korea         | Hospital          | 1                  | 16        |
| Bacteremia                    | 8y  | M      | ALL                   | Not described                     | Korea         | Hospital          | 1                  | 16        |
| Bacteremia                    | <1y | M      | Neonatal sepsis       | Not described                     | Korea         | Hospital          | 1                  | 16        |
| CAPD peritonitis              | 14y | F      | End-stage renal disease| Not described                    | Korea         | Hospital          | 1                  | 16        |
| CR-BSI                        | 1y  | M      | Anaplastic ependymoma | Not described                     | Korea         | Hospital          | 1                  | 16        |
| CR-BSI                        | 17y | M      | Ewing sarcoma         | Not described                     | Korea         | Hospital          | 1                  | 16        |
| CR-BSI                        | 10d | M      | Prematurity/RDS       | Not described                     | Taiwan        | Hospital          | 1                  | 17        |
| Bacteremia                    | 6y  | F      | Lymphoma              | Imipenem/Teicoplanin              | Turkey        | Hospital          | 1                  | 18        |
| Bacteremia                    | 5y  | F      | Neuroblastoma         | Imipenem/Teicoplanin              | Turkey        | Hospital          | 1                  | 18        |
| Bacteremia                    | 11y | M      | Non-Hodgkin lymphoma  | Imipenem/Teicoplanin              | Turkey        | Hospital          | 1                  | 18        |
| Bacteremia                    | 3y  | M      | Acute myeloid leukemia| Imipenem/Teicoplanin              | Turkey        | Hospital          | 1                  | 18        |
| Pneumonia                     | 5y  | M      | None                  | Ampicillin-Sulbactam              | Taiwan        | Community         | 1                  | 19        |
| UTI                           | 5m  | M      | None                  | Ampicillin/Gentamicin             | Taiwan        | Community         | 1                  | 19        |
| Bacteremia*                   | 0m  | -      | Prematurity           | Not described                     | Turkey        | Hospital          | 13                 | 20        |
| Bacteremia                    | 2y  | M      | None                  | Ceftriaxone                       | India         | Community         | 1                  | 20        |
| Bacteremia                    | 7y  | F      | None                  | Cefuroxime                        | Turkey        | Community         | 1                  | 22        |
| Bacteremia                    | 1m  | F      | None                  | Ampicillin/Sulbactam              | Turkey        | Community         | 1                  | 22        |
| Bacteremia                    | 15y | F      | None                  | Cefotaxime                        | Turkey        | Community         | 1                  | 22        |
| Bacteremia                    | 1y  | F      | None                  | Cefuroxime                        | Turkey        | Community         | 1                  | 22        |
| Bacteremia                    | 8y  | F      | Neutropenia-ALL       | Piperacillin/Tazobactam           | Turkey        | Hospital          | 1                  | 22        |
| Bacteremia                    | 8d  | F      | Prematurity           | Meropenem/Vancomycin              | Turkey        | Hospital          | 1                  | 22        |
| Bacteremia                    | 12y | F      | None                  | Piperacillin/Tazobactam           | Turkey        | Hospital          | 1                  | 22        |
| Bacteremia                    | 27d | F      | None                  | Meropenem                         | Turkey        | Hospital          | 1                  | 22        |

ALL = acute lymphoblastic leukemia; CAPD = continuous ambulatory peritoneal dialysis; CNS = central nervous system; CR-BSI = catheter-related bloodstream infection; PSAGN = steroid-induced immunosuppression due to glomerulonephritis; RDS = respiratory distress syndrome; UTI = urinary tract infection; *= case of fatal outcome; **= the author could not define if it was a community or hospital infection.
| Condition                  | Age | Gender | Underlying conditions | Therapy                        | Country | Source of outbreak | Number of patients | Reference |
|----------------------------|-----|--------|-----------------------|--------------------------------|---------|--------------------|--------------------|-----------|
| Bacteremia                 | 3y  | M      | None                  | Cefotaxime                     | Turkey  | Community          | 1                  | 22        |
| Bacteremia                 | 12y | M      | PSAGN                 | Cefuroxime                     | Turkey  | Community          | 1                  | 22        |
| Bacteremia                 | 18d | M      | Prematurity           | Ampicillin/Amikacin            | Turkey  | Community          | 1                  | 22        |
| Bacteremia                 | 9y  | M      | Down syndrome         | Meropenem/Vancomycin           | Turkey  | Community          | 1                  | 22        |
| Bacteremia                 | 1m  | M      | None                  | Ampicillin/Sulbactam           | Turkey  | Community          | 1                  | 22        |
| Bacteremia                 | 3d  | M      | None                  | Ampicillin/Amikacin            | Turkey  | Community          | 1                  | 22        |
| Bacteremia                 | 23d | M      | None                  | Ampicillin/Sulbactam           | Turkey  | Community          | 1                  | 22        |
| Bacteremia                 | 1y  | M      | Imperforate anus      | Ceftazidime                    | Turkey  | Hospital           | 1                  | 22        |
| Bacteremia                 | 23d | M      | Duodenal atresia      | Cefotaxime/Amikacin            | Turkey  | Hospital           | 1                  | 22        |
| Bacteremia                 | 11y | M      | None                  | Meropenem                      | Turkey  | Hospital           | 1                  | 22        |
| Bacteremia                 | 4y  | M      | Neutropenia-ALL       | Piperacillin/Tazobactam        | Turkey  | Hospital           | 1                  | 22        |
| Bacteremia                 | 5y  | M      | Neutropenia-ALL       | Piperacillin/Tazobactam        | Turkey  | Hospital           | 1                  | 22        |
| Bacteremia                 | 10y | M      | None                  | Cefotaxime/Vancomycin          | Turkey  | Community          | 1                  | 22        |
| CR-BSI                     | 4y  | M      | Burn injury           | Meropenem/AHK                 | Turkey  | Hospital           | 1                  | 22        |
| CR-BSI                     | 10y | F      | Neutropenia-ALL       | Piperacillin/Tazobactam        | Turkey  | Hospital           | 1                  | 22        |
| UTI                        | 4m  | F      | None                  | Cefuroxime                     | Turkey  | Community          | 1                  | 22        |
| Bacteremia                 | 1y  | M      | Congenital heart defects | Piperacillin/Tazobactam        | Turkey  | Hospital           | 1                  | 4         |
| Otomastoiditis             | 11y | M      | None                  | Ceftazidime/Clindamycin/Ciprofloxacin | Brazil  | Community          | 1                  | Present Study |
| Bacteremia                 | 6y  | M      | None                  | Cefotaxime/Gentamicin          | Spain   | Community          | 1                  | 23        |
| Cervical adenitis          | 8y  | M      | None                  | Ampicillin                     | Spain   | Community          | 1                  | 23        |
| Brain abscess              | 6a  | F      | None                  | Ampicillin/Chloramphenicol     | USA     | Community          | 1                  | 11        |

ALL = acute lymphoblastic leukemia; CAPD = continuous ambulatory peritoneal dialysis; CNS = central nervous system; CR-BSI= catheter-related bloodstream infection; PSAGN = steroid-induced immunosuppression due to glomerulonephritis; RDS = respiratory distress syndrome; UTI = urinary tract infection; *= case of fatal outcome; **= the author could not define if it was a community or hospital infection.
In conclusion, *S. paucimobilis* is an emerging pathogen in pediatric patients, and not just a contaminant of the hospital environment. The nosocomial or community-acquired infection is related to previous comorbidities, which are mostly associated with immunosuppression due to prematurity and malignancy. However, previously healthy patients may also be involved. Compared with other Gram-negative bacteria, *S. paucimobilis* characteristically present low virulence; however, death has been reported already in one pediatric case. Notwithstanding the resistance to beta-lactam antibiotics, the first choice of treatment consists in carbapenems or quinolones.

**ACKNOWLEDGMENTS**

The authors are thankful to Mr. Mark Binner and Ms. Marcia Hein for reviewing the text.

**REFERENCES**

1. Martínez MA, Ovalle A. [Sphingomonas paucimobilis]. Rev Chilena Infectol. 2013;30(1):49-50. Spanish. http://dx.doi.org/10.4067/S0716-10182013000100007. PMid:23450409.

2. Angelakis E, Roux V, Raoul D. Sphingomonas mucosissima Bacteremia in patient with sickle cell disease. Emerg Infect Dis. 2009;15(1):133-4. http://dx.doi.org/10.3201/ eid1501.080465. PMid:19116079

3. Christakis G, Perlorentzou S, Aslanidou M, et al. Bacteremia caused by Sphingomonas adhesiva in a patient of intensive care unit (ICU): case report and review. Acta Microbiol Hell. 2004;49:385-95.

4. Özdemir M, Pekcan S, Demircili ME, et al. A rare cause of bacteremia in a pediatric patient with Down syndrome: Sphingomonas paucimobilis. Int J Med Sci. 2011;8(7):537-9. http://dx.doi.org/10.7150/ijms.8.537. PMid:21960744

5. Holmes B, Owen RJ, Evans A, Malnick H, Willcox WR. Pseudomonas paucimobilis, a new species isolated from human clinical specimens, the hospital environment, and other sources. Int J Syst Bacteriol. 1990;40(1):235-46. http://dx.doi.org/10.1099/00207713-40-1-235.

6. Yabuuchi E, Yano I, Oyaizu H, Hashimoto Y, Ezaki T, Yamamoto H. Proposals of Sphingomonas paucimobilis gen. nov. and comb. nov., Sphingomonas parapaucimobilis sp. nov., Sphingomonas yanoikuyae sp. nov., Sphingomonas adhaesiva sp. nov., Sphingomonas capsulata comb. nov., and two genospecies of the genus Sphingomonas. Microbiol Immunol. 1990;34(2):99-119. http://dx.doi.org/10.1111/j.1348-0421.1990.tb00996.x. PMid:2111872

7. Richardson LL, Goldberg WM, Kuta KG, et al. Florida's mystery coral-killer identified. Nature. 1998;392(6672):557-8. http://dx.doi.org/10.1038/33302.

8. Sung LL, Yang DI, Hung CC, Ho HT. Evaluation of autoSCAN-W/A and the Vitek GNI+ AutoMicrobic system for identification of non-glucose-fermenting gram-
negative bacilli. J Clin Microbiol. 2000;38(3):1127-30. PMid:10699007.

9. Peel MM, Davis JM, Armstrong WLH, Wilson JR, Holmes B. Pseudomonas paucimobilis from a leg ulcer on a Japanese seaman. J Clin Microbiol. 1979;9(5):561-4. PMid:479356.

10. Crane LR, Tagle LC, Palutke WA. Outbreak of pseudomonas paucimobilis in an intensive care facility. JAMA. 1981;246(9):985-7. http://dx.doi.org/10.1001/jama.1981.03320090047030. PMid:7253184

11. Tiffany KK, Kline MW. Mixed flora brain abscess with Pseudomonas paucimobilis after a penetrating lawn dart injury. Pediatr Infect Dis J. 1988;7(9):667-9. http://dx.doi.org/10.1097/00006454-198809000-00017. PMid:3050862

12. Bourigault C, Daniel L, Jourdain S, et al. Contamination with Sphingomonas paucimobilis: about seven cases isolated in conservation and transport mediums of corneal grafts. Pathol Biol. 2007;55(2):127-30. French. http://dx.doi.org/10.1016/j.patbio.2006.03.001. PMid:16631318.

13. Lemaître D, Elaichouni A, Hundhausen M, et al. Tracheal colonization with Sphingomonas paucimobilis in mechanically ventilated neonates due to contaminated ventilator temperature probes. J Hosp Infect. 1996;32(3):199-206. http://dx.doi.org/10.1016/0195-6701(96)90146-2. PMid:8690883

14. Al-Anazi KA, Abu Jafar S, Al-Jasser AM, et al. Septic shock caused by Sphingomonas paucimobilis bacteremia in a patient with hematopoietic stem cell transplantation. Transpl Infect Dis. 2008;10(2):142-4. http://dx.doi.org/10.1093/clinids/13.6.1072. PMid:1775840

15. Charity RM, Foukas AF. Osteomyelitis and secondary septic arthritis caused by Sphingomonas paucimobilis. Infection. 2005;33(2):93-5. http://dx.doi.org/10.1007/s15010-005-4048-x. PMid:15827879

16. Cheong HS, Wi YM, Moon SY, et al. Clinical features and treatment outcomes of infections caused by Sphingomonas paucimobilis. Infect Control Hosp Epidemiol. 2008;29(10):990-2. http://dx.doi.org/10.1086/591091. PMid:18808348

17. Hsueh PR, Teng LJ, Yang PC, et al. Nosocomial infections caused by Sphingomonas paucimobilis: clinical features and microbiological characteristics. Clin Infect Dis. 1998;26(3):676-81. http://dx.doi.org/10.1086/514595. PMid:9524843

18. Klic A, Senses Z, Kurekci AE, et al. Nosocomial outbreak of Sphingomonas paucimobilis bacteremia in a hematology/oncology unit. Jpn J Infect Dis. 2007;60(6):394-6. PMid:18032843.

19. Lin JN, Lai CH, Chen YH, et al. Sphingomonas paucimobilis bacteremia in humans: 16 case reports and a literature review. J Microbiol Immunol Infect. 2010;43(1):35-42. http://dx.doi.org/10.1016/S1684-1182(10)60005-9. PMid:20434121

20. Mutlu M, Bayramoglu G, Yilmaz G, Saygin B, Aslan Y. Outbreak of Sphingomonas paucimobilis septicemia in a neonatal intensive care unit. Indian Pediatr. 2011;48(9):723-5. http://dx.doi.org/10.1007/s13312-011-0114-x. PMid:21719938

21. Nandy S, Dudeja M, Das AK, Tiwari R. Community acquired bacteremia by Sphingomonas paucimobilis: two rare case reports. J Clin Diagn Res. 2013;7(12):2947-9. PMid:24551684.

22. Bayram N, Devrim I, APA H, Gülfidan G, Türkyılmaz HN, Güney I. Sphingomonas paucimobilis infections in children: 24 case reports. Mediterr J Hematol Infect Dis. 2013;5(1):e2013040. PMid:23795278.

23. Reina J, Bassa A, Llompart I, Portela D, Borrell N. Infections with Pseudomonas paucimobilis: report of four cases and review. Rev Infect Dis. 1991;13(6):1072-6. http://dx.doi.org/10.1093/clinids/13.6.1072. PMid:1775840

24. Ryan MP, Adley CC. Sphingomonas paucimobilis: a persistent Gram-negative nosocomial infectious organism. J Hosp Infect. 2010;75(3):153-7. http://dx.doi.org/10.1016/j.jhin.2010.03.007. PMid:20434794

25. Toh HS, Tay HT, Kuar WK, Weng TC, Tang HJ, Tan CK. Risk factors associated with Sphingomonas paucimobilis infection. J Microbiol Immunol Infect. 2011;44(4):289-95. http://dx.doi.org/10.1016/j.jmii.2010.08.007. PMid:21524965

26. Kawahara K, Uchida K, Aida K. Isolation of an unusual ‘lipid A’ type glycolipid from Pseudomonas paucimobilis. Biochim Biophys Acta. 1982;712(3):571-5. http://dx.doi.org/10.1016/0005-2760(82)90285-5. PMid:7126625

27. Smalley DL. Enzymatic profile of Sphingomonas paucimobilis. J Clin Microbiol. 1982;16(3):564-5. PMid:7130368.

Conflict of interest: None
Submitted on: June 16, 2014
Accepted on: August 6, 2014

Correspondence
Divisão de Clínica Pediátrica – Hospital Universitário
Avenida Prof. Lineu Prestes, 2565 – São Paulo/SP – Brazil
CEP: 05508-000
Phone +55 (11) 97484-0708
E-mail gnbenevides@gmail.com